USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/30048
Title: Treatment strategy for severe combined immunodeficiency in children
Authors: Jayachandran, Jayaraman
Dolapciu, Elena
Keywords: SCID;gene therapy;hematopoietic stem cell transplantation
Issue Date: 2024
Publisher: Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova
Citation: JAYACHANDRAN, Jayaraman; DOLAPCIU, Elena. Treatment strategy for severe combined immunodeficiency in children. In: Revista de Ştiinţe ale Sănătăţii din Moldova = Moldovan Journal of Health Sciences. 2024, vol. 11, nr. 3, anexa 2, p. 667. ISSN 2345-1467.
Abstract: Background. Severe Combined Immunodeficiency (SCID) is a rare but severe pediatric disease that is marked by a severe deficiency of T and B lymphocytes, which results in a high susceptibility to infections. Objective of the study. The purpose of this research is to assess current developments in management of SCID in children by analyzing key trends, clinical findings, and difficulties from academic publications published between 2019 and 2024. Material and methods. A literature review with a primary focus on clinical trials, meta-analyses, and peer-reviewed articles from 2019 to 2024 was conducted. The search terms “Severe Combined Immunodeficiency”, “SCID”, “pediatric immunodeficiency,” “gene therapy,” and “hematopoietic stem cell transplantation” were combined to search PubMed, MEDLINE, and the Cochrane Library. Results. Increased use of newborn screening allows for early diagnosis in these patients. Protective isolation, precautions related to transfusion of blood products, avoidance of live vaccines, and continuous prophylactic anti-infectious treatment should be included in initial management before a definitive diagnosis is made. The gold standard for curative care is still hematopoietic stem cell transplantation (HSCT), with better results now possible because of developments in donor matching and conditioning regimens. Gene therapy as an alternative has emerged, offering the potential for curative therapy for specific genetic variants of SCID. Studies indicate that gene therapy has a high success rate in correcting immune deficiencies. Conclusion. Newborn screening, HSCT advancements, and gene therapy have made significant advances in understanding and treating SCID in the previous five years. However, chronic illnesses need continuing research and international cooperation owing to treatment availability and long-term management difficulties.
metadata.dc.relation.ispartof: Revista de Științe ale Sănătății din Moldova: Moldovan Journal of Health Sciences
URI: https://cercetare.usmf.md/sites/default/files/inline-files/MJHS_11_3_2024_anexa2__site.pdf
http://repository.usmf.md/handle/20.500.12710/30048
ISSN: 2345-1467
Appears in Collections:Revista de Științe ale Sănătății din Moldova : Moldovan Journal of Health Sciences 2024 Vol. 11, Issue 2

Files in This Item:
File Description SizeFormat 
TREATMENT_STRATEGY.pdf137.93 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback